Grand Pharmaceutical Group (HKG:0512) said the first patient was enrolled in its clinical study of GPN00289 in China, a temperature-sensitive embolic agent for advanced liver cancer treatment, according to a Thursday filing with the Hong Kong bourse.
The study assesses the safety and efficacy of the treatment, which combines GPN00289 drug delivery and embolization.
The company's shares were down by 1% in recent trading.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。